02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
22:32 , Aug 16, 2018 |  BC Extra  |  Company News

Management tracks: Achillion, Navidea

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) hired Anthony Gibney as EVP and CBO. He was managing director and co-head of the biotechnology investment banking team at Leerink Partners. Immunotherapy company Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB;...
19:51 , Apr 20, 2018 |  BC Week In Review  |  Company News

Cerveau subsidiary gets rights to Navidea's AD imaging agent

Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB; Tel Aviv:NAVB) granted the Meilleur Technologies Inc. subsidiary of Cerveau Technologies Inc. (Boston, Mass.) worldwide rights to conduct research using Alzheimer's disease imaging agent NAV4694, as well as an exclusive license...
21:05 , Dec 2, 2016 |  BC Week In Review  |  Company News

Navidea, Cardinal Health deal

Navidea will sell its Lymphoseek tilmanocept imaging agent to Cardinal Health for oncology indications for $80 million up front and up to $230 million in annual earn-out and sales milestone payments. Prior to the deal,...
07:00 , Sep 27, 2016 |  BC Extra  |  Company News

Management tracks

Antibody company Prothena Corp. plc (NASDAQ:PRTA) said President and CEO Dale Schenk is taking a medical leave of absence. He will remain on Prothena's board. COO Gene Kinney will lead the company in Schenk's absence....
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Lymphoseek tilmanocept: Phase II started

Navidea began the open-label, U.S. Phase II NAV3-19 trial to evaluate a single peritumoral dose of 50 ug Lymphoseek before surgery in up to 40 patients with cervical cancer who are undergoing lymph node dissection....
07:00 , Jun 29, 2015 |  BC Week In Review  |  Company News

Bind Therapeutics, Navidea deal

Bind partnered non-exclusively with Navidea’s Macrophage Therapeutics subsidiary to develop tumor therapies that combine Bind’s Accurin therapeutic payload delivery nanoparticles with Macrophage’s Manocept mannose binding receptor ( MBR ; CD206 )-targeted technology platform. Both companies...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Company News

Alseres, Navidea deal

The partners terminated a 2012 deal granting Navidea exclusive, worldwide rights to develop and commercialize Altropane ( NAV5001 ). Navidea will be eligible to receive a milestone payment upon FDA approval plus royalties. Navidea said...
07:00 , May 18, 2015 |  BC Week In Review  |  Financial News

Navidea completes debt financing

Navidea Biopharmaceuticals Inc. (NYSE-M:NAVB), Dublin, Ohio   Business: Diagnostic   Date completed: 2015-05-11   Type: Debt financing   Raised: $50 million   Investor: CRG   Note: Navidea drew down $50 million of a new $60...
01:56 , May 14, 2015 |  BC Extra  |  Financial News

Navidea takes $60M loan

Navidea Biopharmaceuticals Inc. (NYSE-M: NAVB) said it will receive a loan of up to $60 million from CRG, including an initial $50 million at closing. Navidea plans to retire its debt from Oxford Finance LLC...